Association of GSK-3β genetic variation with GSK-3β expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia

American Journal of Psychiatry

Volumn 170, Issue 8, 2013, Pages 868-876

  Blasi, Giuseppe ^a   Napolitano, Francesco ^a   Ursini, Gianluca ^a   Di Giorgio, Annabella ^a   Caforio, Grazia ^a   Taurisano, Paolo ^a   Fazio, Leonardo ^a   Gelao, Barbara ^a   Attrotto, Maria Teresa ^a   Colagiorgio, Lucia ^a   Todarello, Giovanna ^a   Piva, Francesco ^a   Papazacharias, Apostolos ^a   Masellis, Rita ^a   Mancini, Marina ^a   Porcelli, Annamaria ^a   Romano, Raffaella ^a   Rampino, Antonio ^a   Quarto, Tiziana ^a   Giulietti, Matteo ^a   Lipska, Barbara K ^a   Kleinman, Joel E ^a   Popolizio, Teresa ^a   Weinberger, Daniel R ^a   Usiello, Alessandro ^a   Bertolino, Alessandro ^a   more..

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA;

ADULT; ARTICLE; COMPUTER PREDICTION; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLYCOGEN SYNTHASE KINASE 3BETA GENE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84883367748     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12070908     Document Type: Article

References (40)

1. Yao HB, Shaw PC, Wong CC, Wan DC: Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain. J Chem Neuroanat 2002; 23: 291-297
2. Hur EM, Zhou FQ: GSK3 signalling in neural development. Nat Rev Neurosci 2010; 11: 539-551
3. Freyberg Z, Ferrando SJ, Javitch JA: Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010; 167: 388-396
4. Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669
5. McGuffin P, Riley B, Plomin R: Genomics and behavior. Toward behavioral genomics. Science 2001; 291: 1232-1249
6. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR: Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000; 57: 907-913
7. Souza RP, Romano-Silva MA, Lieberman JA, Meltzer HY, Wong AH, Kennedy JL: Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) 2008; 200: 177-186
8. Li M, Mo Y, Luo XJ, Xiao X, Shi L, Peng YM, Qi XB, Liu XY, Yin LD, Diao HB, Su B: Genetic association and identification of a functional SNP at GSK3b for schizophrenia susceptibility. Schizophr Res 2011; 133: 165-171
9. Kozlovsky N, Belmaker RH, Agam G: Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 2000; 157: 831-833
10. Amar S, Shaltiel G, Mann L, Shamir A, Dean B, Scarr E, Bersudsky Y, Belmaker RH, Agam G: Possible involvement of postdopamine D2 receptor signalling components in the pathophysiology of schizophrenia. Int J Neuropsychopharmacol 2008; 11: 197-205
11. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA: Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004; 36: 131-137
12. Woodgett JR: Judging a protein by more than its name: GSK-3. Sci STKE 2001; 2001:re12
13. Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005;10: 40-68
14. Li YC, Gao WJ: GSK-3b activity and hyperdopamine-dependent behaviors. Neurosci Biobehav Rev 2011; 35: 645-654
15. Seamans JK, Yang CR: The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004; 74: 1-58
16. Beaulieu JM, Gainetdinov RR, Caron MG: The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007; 28: 166-172
17. Blasi G, Napolitano F, Ursini G, Taurisano P, Romano R, Caforio G, Fazio L, Gelao B, Di Giorgio A, Iacovelli L, Sinibaldi L, Popolizio T, Usiello A, Bertolino A: DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci USA 2011; 108: 1158-1163
18. Lovestone S, Killick R, Di Forti M, Murray R: Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 2007; 30: 142-149
19. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD, Buchanan DD, Silburn PA, Halliday GM, Schofield PR: GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005; 58: 829-839
20. Inkster B, Nichols TE, Saemann PG, Auer DP, Holsboer F, Muglia P, Matthews PM: Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. Arch Gen Psychiatry 2009; 66: 721-728
21. Benedetti F, Poletti S, Radaelli D, Bernasconi A, Cavallaro R, Falini A, Lorenzi C, Pirovano A, Dallaspezia S, Locatelli C, Scotti G, Smeraldi E: Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-b activity. Genes Brain Behav 2010; 9: 365-371
22. Lee YJ, Kim YK: The impact of glycogen synthase kinase 3b gene on psychotic mania in bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1303-1308
23. Saus E, Soria V, Escaramís G, Crespo JM, Valero J, Gutiérrez-Zotes A, Martorell L, Vilella E, Menchón JM, Estivill X, Gratacòs M, Urretavizcaya M: A haplotype of glycogen synthase kinase 3b is associated with early onset of unipolar major depression. Genes Brain Behav 2010; 9: 799-807
24. Meyer-Lindenberg A, Nichols T, Callicott JH, Ding J, Kolachana B, Buckholtz J, Mattay VS, Egan M, Weinberger DR: Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry 2006; 11: 867-877
25. Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT, Colantuoni EA, Elkahloun AG, Herman MM, Weinberger DR, Kleinman JE: Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature 2011; 478: 519-523
26. Castri P, Iacovelli L, De Blasi A, Giubilei F, Moretti A, Tari Capone F, Nicoletti F, Orzi F: Reduced insulin-induced phosphatidylinositol- 3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease. Eur J Neurosci 2007; 26: 2469-2472
27. Bertolino A, Taurisano P, Pisciotta NM, Blasi G, Fazio L, Romano R, Gelao B, Lo Bianco L, Lozupone M, Di Giorgio A, Caforio G, Sambataro F, Niccoli-Asabella A, Papp A, Ursini G, Sinibaldi L, Popolizio T, Sadee W, Rubini G: Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance. PLoS ONE 2010; 5:e9348
28. Oldfield RC: The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971; 9: 97-113
29. Blasi G, Mattay VS, Bertolino A, Elvevåg B, Callicott JH, Das S, Kolachana BS, Egan MF, Goldberg TE, Weinberger DR: Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci 2005; 25: 5038-5045
30. Blasi G, Goldberg TE, Elvevåg B, Rasetti R, Bertolino A, Cohen J, Alce G, Zoltick B, Weinberger DR, Mattay VS: Differentiating allocation of resources and conflict detection within attentional control processing. Eur J Neurosci 2007; 25: 594-602
31. Blasi G, Taurisano P, Papazacharias A, Caforio G, Romano R, Lobianco L, Fazio L, Di Giorgio A, Latorre V, Sambataro F, Popolizio T, Nardini M, Mattay VS, Weinberger DR, Bertolino A: Nonlinear response of the anterior cingulate and prefrontal cortex in schizophrenia as a function of variable attentional control. Cereb Cortex 2010; 20: 837-845
32. Callicott JH, Mattay VS, Bertolino A, Finn K, Coppola R, Frank JA, Goldberg TE, Weinberger DR: Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex 1999; 9: 20-26
33. First MB, Gibbon M, Spitzer RL, Williams JBW: Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders- Research Version. New York, Biometrics Research, 1996
34. Isken O, Maquat LE: Quality control of eukaryotic mRNA: safeguarding cells from abnormal mRNA function. Genes Dev 2007; 21: 1833-1856
35. Melamud E, Moult J: Structural implication of splicing stochastics. Nucleic Acids Res 2009; 37: 4862-4872
36. Kim WY, Wang X, Wu Y, Doble BW, Patel S, Woodgett JR, Snider WD: GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci 2009; 12: 1390-1397
37. Bertolino A, Caforio G, Petruzzella V, Latorre V, Rubino V, Dimalta S, Torraco A, Blasi G, Quartesan R, Mattay VS, Callicott JH, Weinberger DR, Scarabino T: Prefrontal dysfunction in schizophrenia controlling for COMT Val158Met genotype and workingmemory performance. Psychiatry Res 2006; 147: 221-226
38. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P; International Schizophrenia Consortium: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-752
39. Drapier D, Surguladze S, Marshall N, Schulze K, Fern A, Hall MH, Walshe M, Murray RM, McDonald C: Genetic liability for bipolar disorder is characterized by excess frontal activation in response to a working memory task. Biol Psychiatry 2008; 64: 513-520
40. Durston S, Mulder M, Casey BJ, Ziermans T, van Engeland H: Activation in ventral prefrontal cortex is sensitive to genetic vulnerability for attention-deficit hyperactivity disorder. Biol Psychiatry 2006; 60: 1062-1070